VC firm Piv­otal clos­es sec­ond $389M ther­a­peu­tics fund to cre­ate com­pa­nies and back pub­lic biotechs

Piv­otal bioVen­ture Part­ners Fund II has ful­ly closed at $389 mil­lion, and the Bay Area firm still has more than 75% of that fund­ing to de­ploy af­ter a first close dur­ing the “peak of the mar­ket” in mid-2021, man­ag­ing gen­er­al part­ner Rob Hopfn­er told End­points News.

The fund, un­veiled Mon­day morn­ing, is about $90 mil­lion larg­er than its first go-around, which was dis­closed in March 2017. Piv­otal bioVen­ture Part­ners has since cre­at­ed com­pa­nies out of aca­d­e­m­ic re­search, like schiz­o­phre­nia and CNS drug­mak­er Map­Light; formed biotechs based on as­set carve-outs from Big Phar­ma, like Evom­mune; and backed pub­lic biotechs like Vax­cyte, which has raised large amounts of mon­ey for late-stage tri­als of its pneu­mo­coc­cal vac­cine, which could com­pete with Pfiz­er’s Pre­vnar.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER